Wait what? The way I read this, is that the FDA can issue another Voucher?
Trofinetide has been granted Fast Track Status and Orphan Drug Designation for the treatment of Rett syndrome in the United States. An NDA with Orphan Drug Designation is eligible for priority review. Trofinetide has also been granted Rare Pediatric Disease (RPD) designation by the FDA. With such designation, Acadia expects to be awarded a Priority Review Voucher if the NDA is approved.
Why would they type "to be awareded a Priority Review Voucher"? I thought they already have one for Trofinetide?
- Forums
- ASX - By Stock
- NEU
- Acadia
Acadia, page-6
- There are more pages in this discussion • 672 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$20.25 |
Change
0.430(2.17%) |
Mkt cap ! $2.585B |
Open | High | Low | Value | Volume |
$19.89 | $20.39 | $19.77 | $5.715M | 283.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 355 | $20.22 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.29 | 302 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 248 | 20.200 |
1 | 845 | 20.160 |
1 | 2308 | 20.140 |
3 | 1963 | 20.130 |
1 | 951 | 20.110 |
Price($) | Vol. | No. |
---|---|---|
20.320 | 1118 | 2 |
20.330 | 845 | 1 |
20.350 | 3000 | 1 |
20.360 | 845 | 1 |
20.390 | 845 | 1 |
Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
Last
$20.22 |
  |
Change
0.430 ( 2.40 %) |
|||
Open | High | Low | Volume | ||
$19.86 | $20.40 | $19.77 | 85257 | ||
Last updated 15.59pm 07/05/2024 ? |
Featured News
NEU (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
Previous Video
Next Video
SPONSORED BY The Market Online